TABLE 1.
Utility of a genotypic result of CTX-M/KPC/NDM to predict ceftriaxone, ceftazidime, aztreonam, and piperacillin-tazobactam resultsa
| Phenotype and drug treatment |
No. negative for CTX-M, KPC, and NDM | No. positive for CTX-M, KPC, and/or NDM | % VME | If negative for CTX-M, KPC, and NDM, presence of other BLA, n (%) |
|||
|---|---|---|---|---|---|---|---|
| AmpC | TEM | SHV | Neg | ||||
| Resistant | |||||||
| CRO | 127 | 556 | 18.6 | 43 (33.9) | 1 (0.8) | 49 (38.6) | 34 (26.8) |
| CAZ | 92 | 404 | 18.5 | 34 (37.0) | 1 (1.1) | 46 (50.0) | 11 (12.0) |
| TZP | 73 | 202 | 26.5 | 7 (9.6) | 2 (2.7) | 25 (34.2) | 39 (53.4) |
| ATM | 114 | 501 | 18.5 | 34 (29.8) | 1 (0.9) | 50 (43.9) | 29 (25.4) |
| Nonsusceptible | |||||||
| CRO | 145 | 557 | 20.7 | 49 (33.8) | 1 (0.6) | 53 (36.6) | 42 (29.0) |
| CAZ | 109 | 436 | 20.0 | 39 (35.7) | 1 (0.9) | 49 (45.0) | 20 (18.3) |
| TZP | 93 | 250 | 27.1 | 30 (32.3) | 3 (0.3) | 16 (17.2) | 44 (47.3) |
| ATM | 139 | 533 | 20.7 | 40 (28.8) | 1 (0.7) | 51 (36.7) | 47 (33.8) |
a
CRO, ceftriaxone, CAZ, ceftazidime, TZP, piperacillin-tazobactam, ATM, aztreonam, BLA, beta-lactamase.